1887

Chapter 46 : Antibacterial Treatment of Leprosy

Author: J. Grosset
Content Type: Reference
Publication Year: 2005

Category: Bacterial Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Antibacterial Treatment of Leprosy, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap46-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap46-2.gif

Abstract:

Acquired resistance of to the thioamides has been demonstrated in patients suffering from lepromatous leprosy treated with thioamides alone. Only the antibacterial treatment of leprosy, the principles on which it is based, the combinations with recommended antibiotics, and the results obtained to date in the field are discussed in this chapter. The whole argument behind modern chemotherapy of leprosy is based on the treatment of lepromatous or multibacillary leprosy, in the same way that the rationale for the chemotherapy of tuberculosis is based on the treatment of patients suffering from cavitary pulmonary tuberculosis. Dapsone, rifampin, and clofazimine therefore are automatically part of the initial phase of the chemotherapy of leprosy. From 10 at the beginning of treatment, the total number of viable bacilli in a patient suffering from multibacillary leprosy therefore fell to 10! The majority of susceptible bacilli and mutants resistant to dapsone and clofazimine, which by definition are susceptible to rifampin, were eliminated. The first reason for continuing treatment beyond the first doses of rifampin is to prevent the risk of selection of rifampin-resistant bacilli. The second reason is that after very short-term multidrug therapy in patients suffering from Bamako multibacillary leprosy, it was found that the shorter the duration of antibiotic administration, the earlier relapses occurred. It is difficult to reduce the duration of the multidrug therapy recommended by the WHO. It is based on the combination of the three best-tolerated antibiotics, rifampin, dapsone, and clofazimine, of which only rifampin is highly bactericidal.

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Antibacterial Treatment of Leprosy
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch46-1,webId=/content/author/10.1128/9781555815929.ch46-1,properties={foaf_givenname=J., foaf_name=J. Grosset, foaf_surname=Grosset}]]
Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46fig01
Figure 1
10.1128/9781555815929/f1168-01_thmb.gif
10.1128/9781555815929/f1168-01.gif
Image of Figure 1
Figure 1

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815929.ch46.ch46fig02
Figure 2
10.1128/9781555815929/f1170-01_thmb.gif
10.1128/9781555815929/f1170-01.gif
Image of Figure 2
Figure 2

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815929.ch46.ch46fig03
Figure 3
10.1128/9781555815929/f1171-01_thmb.gif
10.1128/9781555815929/f1171-01.gif
Image of Figure 3
Figure 3

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815929.ch46.ch46fig04
Figure 4
10.1128/9781555815929/f1171-02_thmb.gif
10.1128/9781555815929/f1171-02.gif
Image of Figure 4
Figure 4

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815929.ch46.ch46fig05
Figure 5
10.1128/9781555815929/f1173-01_thmb.gif
10.1128/9781555815929/f1173-01.gif
Image of Figure 5
Figure 5

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815929.ch46.ch46fig06
Figure 6
10.1128/9781555815929/f1175-01_thmb.gif
10.1128/9781555815929/f1175-01.gif
Image of Figure 6
Figure 6

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815929.ch46
1. Banerjee DK,, Ellard GA,, Gammon T,, Waters MFR, 1974, Some observations on the pharmacology of clofazimine, Am J Trop Med Hyg, 23, 1110– 1115.
2. Barry VC,, Conalty ML, 1958, Antituberculosis activity in the phenazine series. II. N 3-substituted anilino-apo-safranines (rimino-compounds) and some derivatives, Am Rev Tuberc Pulm Dis, 78, 62– 73.
3. Becx-Bleuminck M, 1989, Operational aspects of multidrug therapy, Int J Lepr Other Mycobact Dis, 57, 540– 541.
4. Boerrigter G,, Ponnighaus JM,, Fine PEM, 1988, Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi, Int J Lepr Other Mycobact Dis, 56, 408– 417.
5. Cartel JL,, Millan J,, Guelpa-Lauras CC,, Grosset JH, 1983, Hepatitis in leprosy patients treated with a daily combination of dapsone, rifampin, and a thioamide, Int J Lepr Other Mycobact Dis, 51, 461– 465.
6. Cartel JL,, Naudillon Y,, Artus JC,, Grosset JH, 1985, Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin, Int J Lepr Other Mycobact Dis, 53, 15– 18.
7. Cochrane RG,, Ramanujam K,, Paul H,, Russel D, 1949, Two-and-a-half years’ experimental work on the sulphone group of drugs, Lepr Rev, 20, 4– 64.
8. Colston MJ,, Hilson GRF,, Banerjee DK, 1978, The proportional bactericidal test, a method for assessing bactericidal activity of drugs against Mycobacterium leprae in mice, Lepr Rev, 49, 7– 15.
9. Constant-Desportes M,, Guelpa-Lauras CC,, Carolina JC,, Leoture A,, Grosset JH,, Sansarricq H, 1991, A case of relapse with drug-susceptible M. leprae after multidrug therapy, Int J Lepr Other Mycobact Dis, 59, 242– 247.
10. Ellard GA, 1990, The chemotherapy of leprosy. Part 1, Int J Lepr Other Mycobact Dis, 58, 704– 716.
11. Ellard GA, 1991, The chemotherapy of leprosy. Part 2, Int J Lepr Other Mycobact Dis, 59, 82– 94.
12. Ellard GA,, Pannikar VK,, Jesudasan K,, Christian M, 1988, Clofazimine and dapsone compliance in leprosy, Lepr Rev, 59, 205– 213.
13. Faget GH,, Johansen FA,, Ross H, 1942, Sulfanilamide in the treatment of leprosy, Public Health Rep, 57, 1892– 1899.
14. Faget GH,, Pogge RC,, Johansen FA,, Dinan JF,, Prejean BM,, Eccles CG, 1943, The promin treatment of leprosy: a progress report, Public Health Rep, 58, 1729– 1741.
15. Franzblau SG,, White KE,, O’Sullivan JF, 1989, Structure-activity relationships of tetramethylpiperidine-substituted phenazines against Mycobacterium leprae in vitro, Antimicrob Agents Chemother, 53, 2004– 2005.
16. Gelber RH, 1987, Activity of minocycline in Mycobacterium leprae-infected mice, J Infect Dis, 18, 236– 239.
17. Gerald L,, Mandell MA, 1990, Drugs used in the chemotherapy of tuberculosis and leprosy, p 1146– 1164, in Goodman and Gilman, The Pharmacological Basis of Therapeutics. Antimicrobial Agents, 8th ed, Pergamon Press, Inc.
18. Grosset J, 1992, Treatment of tuberculosis in HIV infection, Tuber Lung Dis, 71, 378– 383.
19. Grosset JH, 1986, Recent developments in the field of multidrug therapy and future research in chemotherapy of leprosy, Lepr Rev, 57, Suppl, 223– 234.
20. Grosset JH,, Guelpa-Lauras CC,, Bobin P,, Brucker G,, Cartel JL,, Constant-Desportes M,, Flageul B,, Frederic M,, Guillaume JC,, Milian J, 1989, Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin, Int J Lepr Other Mycobact Dis, 57, 607– 614.
21. Grosset JH,, Guelpa-Lauras CC,, Perani EG,, Beoletto C, 1988, Activity of ofloxacin against Mycobacterium leprae in the mouse, Int J Lepr Other Mycobact Dis, 56, 259– 264.
22. Grosset JH,, Ji B,, Guelpa-Lauras CC,, Perani EG,, Ndeli L, 1990, Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy, Int J Lepr Other Mycobact Dis, 58, 281– 295.
23. Grumbach F, 1960, Activité anti tuberculeuse expérimentale de deux dérivés de phénazine pigmentée (B663 et B720) seuls et associés à d’autres antituberculeux (isoniazide et éthionamide), Ann Inst Pasteur, 98, 567– 585.
24. Guelpa-Lauras CC,, Cartel JL,, Constant-Desportes M,, Milian J,, Bobin P,, Guidi C,, Brucker G,, Flageul B,, Guillaume JC,, Pichet C,, Remey JC,, Grosset JH, 1987, Primary and secondary dapsone resistance to M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal and Paris between 1980 and 1985, Int J Lepr Other Mycobact Dis, 55, 672– 679.
25. Guelpa-Lauras CC,, Perani EG,, Giroir AM,, Grosset JH, 1987, Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse, Int J Lepr Other Mycobact Dis, 55, 70– 77.
26. Hamilton EJ,, Eidus L,, Little E, 1962, A comparative study in vivo of isoniazid and alpha-ethylthioisonicotinamide, Am Rev Respir Dis, 85, 407– 412.
27. Hastings RC, 1985, Leprosy, Longman Group Limited.
28. Honoré N,, Cole S, 1993, Molecular basis of rifampin resistance in Mycobacterium leprae, Antimicrob Agents Chemother, 37, 414– 418.
29. Husser JA,, Traore I,, Daumerie D, 1994, Activity of two doses of rifampin against Mycobacterium leprae, Int J Lepr Other Mycobact Dis, 62, 359– 364.
30. Jacobson RR, 1985, Chapter 9, in RC Hastings, ed, Treatment in Leprosy, Churchill Livingstone.
31. Jacobson RR,, Hastings RC, 1976, Rifampin-resistant leprosy, Lancet, ii, 1304– 1305.
32. Jamet P,, Ji B, 1995, Relapse after long-term follow up of multi-bacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis, 63, 195– 201.
33. Jamet P,, Traore I,, Husser JA,, Ji B, 1992, Short-term trial of clofazimine in previously untreated lepromatous leprosy, Int J Lepr Other Mycobact Dis, 60, 542– 548.
34. Jenner PJ,, Ellard GA, 1981, High-performance liquid chromatographic determination of ethionamide and prothionamide in body fluids, J Chromatogr, 22, 245– 251.
35. Jenner PJ,, Ellard GA,, Gruent PJK,, Aber VR, 1984, Comparison of blood levels and urinary excretion of ethionamide and prothion-amide in man, J Antimicrob Chemother, 12, 267– 277.
36. Jesudassan K,, Vijayakumaran P,, Pannikar VK,, Christian M, 1988, Impact of MDT on leprosy as measured by selective indicators, Lepr Rev, 59, 215– 223.
37. Ji B, 1985, Drug resistance in leprosy—a review, Lepr Rev, 56, 265– 278.
38. Ji B,, Chen J,, Wang C,, Xia G, 1984, Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy, Lepr Rev, 55, 283– 289.
39. Ji B,, Grosset J, 1990, Recent advances in the chemotherapy of leprosy, Lepr Rev, 61, 313– 329.
40. Ji B,, Jamet P,, Perani EG,, Bobin P,, Grosset JH, 1993, Powerful bactericidal activities of clarithromycin and minocycline against M. leprae in lepromatous leprosy, J Infect Dis, 168, 188– 190.
41. Ji B,, Perani EG,, Grosset JH, 1991, Effectiveness of clarithromycin and minocycline alone or in combination against Mycobacterium leprae infection in mice, Antimicrob Agents Chemother, 35, 579– 581.
42. Katoch K,, Ramanathan U,, Natrajan M,, Bagga AK,, Bhatia AS,, Saxena RK,, Ramu G, 1989, Relapses in paucibacillary patients after treatment with three short-term regimens containing rifampicin, Int J Lepr Other Mycobact Dis, 57, 458– 464.
43. Lesobre R,, Ruffino J,, Teyssier L,, Achard F,, Brefort G, 1968, Les icteres au cours du traitement par la rifampicine, Rev Tuberc Pneumol, 33, 393– 403.
44. Levy L,, Shepard CC,, Fasal P, 1972, Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant Mycobacterium leprae, Am J Trop Med Hyg, 21, 315– 321.
45. Levy L,, Shepard CC,, Fasal P, 1976, The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg, Int J Lepr Other Mycobact Dis, 44, 183– 187.
46. Lowe J, 1950, Treatment of leprosy with diamino-diphenyl sulfone by mouth, Lancet, I, 145– 150.
47. Lowe J,, Smith M, 1949, The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones, Int J Lepr, 17, 181– 195.
48. McDermott W, 1958, Microbial persistence, Yale J Biol Med, 30, 257– 329.
49. Mechali D,, Coulaud JP, 1988, Antilépreux, p 1574– 1583, in Giroud JP,, Mathe G,, Meyniel G, ed, Pharmacologie clinique. Bases de la therapeutique, 2nd ed.
50. Mitchison DA, 1988, The action of antituberculosis drugs in short-course chemotherapy, Tubercle, 68, 219– 225.
51. Morrison NE,, Marley GM, 1976, Clofazimine binding studies with deoxyribonucleic acid, Int J Lepr Other Mycobact Dis, 44, 475– 481.
52. Ndeli L,, Guelpa-Lauras CC,, Perani EG,, Grosset JH, 1990, Effectiveness of pefloxacin in the treatment of lepromatous leprosy, Int J Lepr Other Mycobact Dis, 58, 12– 18.
53. Pattyn SR,, Ropier MT,, Rollier R,, Verdoahaege G, 1975, Sensibilité envers la dapsone, la sulfaméthoxypyridazine et l’éthion-amide de Mycobacterium leprae provenant de malades traités par ces substances, Int J Lepr Other Mycobact Dis, 43, 356– 362.
54. Pettit JHS,, Rees RJW, 1964, Sulphone resistance in leprosy. An experimental and clinical study, Lancet, II, 673– 674.
55. Rees RJW,, Pearson JMH,, Waters MFR, 1970, Experimental and clinical studies on rifampicin in the treatment of leprosy, Br Med J, 1, 89– 92.
56. Rist N, 1960, L’activité antituberculeuse de l’éthionamide (l’alpha-éthylthioisonicotinamide ou 1314 Th). Etude expérimentale et clinique, Adv Tuberc Res, 10, 69– 126.
57. Shepard CC, 1974, Recent developments in the chemotherapy and chemoprophylaxis of leprosy, Leprologia (Argentina), 19, 230– 236.
58. Shepard CC,, Chang YT, 1962, Effect of several anti-leprosy drugs on multiplication of human leprosy bacilli in footpads of mice, Proc Soc Exp Biol Med, 102, 636– 638.
59. Shepard CC,, Levy L,, Fasal P, 1974, Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae, Am J Trop Med Hyg, 23, 1120– 1124.
60. Shepard CC,, Walker LL,, Van Landingham RM,, Redus M, 1971, Kinetic testing of drugs against Mycobacterium leprae in mice: activity of cephaloridine, rifampin, streptovaricin, and viomycin, Am J Trop Med Hyg, 20, 616– 620.
61. Simon E,, Veres E,, Banki G, 1969, Changes in SGOT activity during treatment with ethionamide, Scand J Respir Dis, 50, 314– 322.
62. Thelep Subcommittee on Clinical Trials of the Chemotherapy of Leprosy Scientific Working Group of the UNDPI/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 1987, Persisting Mycobacterium leprae among Thelep trial patients in Bamako and Chingleput, Lepr Rev, 58, 325– 337.
63. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 1989, Leprosy, p 93– 100, in Ninth Programme Report: Tropical Diseases, Progress in International Research, 1987–1988, WHO, Geneva.
64. Warndoff-Vandiepen T, 1982, Clofazimine-resistant leprosy: a case report, Int J Lepr Other Mycobact Dis, 50, 139– 142.
65. WHO Expert Committee on Leprosy, 1977, Fifth Report, Tech Rep Ser 607, World Health Organization, Geneva.
66. WHO Expert Committee on Leprosy, 1988, Sixth Report, Tech Rep Ser 768, World Health Organization, Geneva.
67. WHO Study Group, 1982, Chemotherapy of leprosy for control programmes, Tech Rep Ser 675, World Health Organization, Geneva.
68. Young DB,, Cole ST, 1993, Leprosy, tuberculosis, and the new genetics, J Bacteriol, 175, 1– 6.

Tables

Antibacterial Treatment of Leprosy
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch46-1,webId=/content/author/10.1128/9781555815929.ch46-1,properties={foaf_givenname=J., foaf_name=J. Grosset, foaf_surname=Grosset}]]
Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46tab01
Table 1
Generic image for table
Table 1

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46tab02
Table 2
Generic image for table
Table 2

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46tab03
Table 3
Generic image for table
Table 3

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46tab04
Table 4
Generic image for table
Table 4

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46
/content/10.1128/9781555815929.ch46.ch46tab05
Table 5
Generic image for table
Table 5

Citation: Grosset J. 2005. Antibacterial Treatment of Leprosy, p 1168-1178. In Bryskier, M.D. A (ed), Antimicrobial Agents. ASM Press, Washington, DC. doi: 10.1128/9781555815929.ch46

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error